HomeCompareNS vs JNJ

NS vs JNJ: Dividend Comparison 2026

NS yields 7.29% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.1K in total portfolio value· pulled ahead in Year 9
10 years
NS
NS
● Live price
7.29%
Share price
$21.96
Annual div
$1.60
5Y div CAGR
-11.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.3K
Annual income
$287.71
Full NS calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — NS vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NS
Annual income on $10K today (after 15% tax)
$619.31/yr
After 10yr DRIP, annual income (after tax)
$244.55/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $3,792.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NS + JNJ for your $10,000?

NS: 50%JNJ: 50%
100% JNJ50/50100% NS
Portfolio after 10yr
$28.4K
Annual income
$2,518.79/yr
Blended yield
8.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NS
Analyst Ratings
6
Buy
13
Hold
3
Sell
Consensus: Hold
Price Target
$20.25
-7.8% upside vs current
Range: $19.50 — $21.00
Altman Z
1.0
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NS buys
8
JNJ buys
0
PoliticianChamberTickerTypeAmountDate
Chip Roy🏢 House$NS▼ Sell$1,001 - $15,0002024-04-10
Bill Hagerty🏛 Senate$NS▼ Sell$50,001 - $100,0002021-12-29
Bill Hagerty🏛 Senate$NS▼ Sell$50,001 - $100,0002021-12-29
Mark Dr Green🏢 House$NS▼ Sell$500,001 - $1,000,0002021-12-21
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-10-06
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-09-27
Mark Dr Green🏢 House$NS▲ Buy$50,001 - $100,0002021-09-14
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-09-01
Mark Dr Green🏢 House$NS▼ Sell$250,001 - $500,0002021-08-19
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-07-09
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNSJNJ
Forward yield7.29%2.14%
Annual dividend / share$1.60$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-11.4%28%
Portfolio after 10y$26.3K$30.5K
Annual income after 10y$287.71$4,749.88
Total dividends collected$4.6K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$20.25$228.73

Year-by-year: NS vs JNJ ($10,000, DRIP)

YearNS PortfolioNS Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,346$645.54$10,594$274.49+$752.00NS
2$12,746$606.45$11,294$360.69+$1.5KNS
3$14,203$564.16$12,133$476.91+$2.1KNS
4$15,717$520.52$13,156$635.42+$2.6KNS
5$17,294$476.98$14,432$854.61+$2.9KNS
6$18,940$434.59$16,056$1,162.76+$2.9KNS
7$20,660$394.09$18,175$1,604.53+$2.5KNS
8$22,462$355.95$21,009$2,252.68+$1.5KNS
9← crossover$24,354$320.45$24,911$3,229.73$557.00JNJ
10$26,347$287.71$30,458$4,749.88$4.1KJNJ

NS vs JNJ: Complete Analysis 2026

NSStock

NuStar Energy L.P. engages in the terminalling, storage, and marketing of petroleum products in the United States and internationally. The company also engages in the transportation of petroleum products and anhydrous ammonia. It operates through three segments: Pipeline, Storage, and Fuels Marketing. The Pipeline segment transports refined products, crude oil, and anhydrous ammonia. The Storage segment owns terminal and storage facilities, which offer storage, handling, and other services for petroleum products, crude oil, specialty chemicals, renewable fuels, and other liquids; and pilotage, tug assistance, line handling, launch, emergency response, and other ship services. The Fuels Marketing segment is involved in bunkering operations in the Gulf Coast; blending operations; and purchase of petroleum products for resale. As of December 31, 2021, it had 3,205 miles of refined product pipelines and 2,230 miles of crude oil pipelines in Texas, Oklahoma, Kansas, Colorado, and New Mexico; a 2,050-mile refined product pipeline originating in southern Kansas and terminating at Jamestown, North Dakota; a 450-mile refined product pipeline originating at Marathon Petroleum Corporation's Mandan, North Dakota refinery and terminating in Minneapolis, Minnesota; a 2,000-mile anhydrous ammonia pipeline; and 29 terminal and storage facilities, which offer approximately 44.2 million barrels of storage capacity. The company was incorporated in 1999 and is headquartered in San Antonio, Texas.

Full NS Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NS vs SCHDNS vs JEPINS vs ONS vs KONS vs MAINNS vs ABBVNS vs MRKNS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.